Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 43, 192-196, January 1, 1983]
© 1983 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chang, R. L.
Right arrow Articles by Conney, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chang, R. L.
Right arrow Articles by Conney, A. H.

Tumorigenicity of Enantiomers of Chrysene 1,2-Dihydrodiol and of the Diastereomeric Bay-Region Chrysene 1,2-Diol-3,4-epoxides on Mouse Skin and in Newborn Mice

Richard L. Chang1, Wayne Levin, Alexander W. Wood, Haruhiko Yagi, Masao Tada, Kamlesh P. Vyas, Donald M. Jerina and Allan H. Conney

Department of Biochemistry and Drug Metabolism, Hoffmann-La Roche Inc., Nutley, New Jersey 07110 [R. L. C., W. L., A. W. W., A. H. C.], and Laboratory of Bioorganic Chemistry, National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases, NIH, Bethesda, Maryland 20205 [H. Y., M. T., K. P. V., D. M. J.]

The tumorigenicity of chrysene, (+)- and (-)-trans-1,2-dihydroxy-1,2-dihydrochrysene (chrysene 1,2-dihydrodiol), and the (+)- and (-)-enantiomers of the diastereomeric bay-region chrysene 1,2-diol-3,4-epoxides was assessed in two tumor models. A single topical application of 0.4 or 1.2 µmol of the chrysene derivatives on mouse skin followed by 25 weeks of promotion with 12-O-tetradecanoylphorbol-13-acetate revealed that (-)-chrysene 1,2-dihydrodiol had approximately twice the tumor-initiating activity of chrysene, while the (+)-enantiomer had no significant tumorigenic activity. Of the four isomers of chrysene 1,2-diol-3,4-epoxide, only (+)-1ß,2{alpha}-dihydroxy-3{alpha},4{alpha}-epoxy-1,2,3,4-tetrahydrochrysene [(+)-diolepoxide 2], in which the benzylic hydroxyl group and epoxide oxygen are trans, had significant tumorigenic activity. The (+)-diol-epoxide 2 isomer had tumor-initiating activity that was equivalent to the activity of the parent hydrocarbon. In newborn mice, a total dose of 0.7 or 1.4 µmol of compound divided into three i.p. injections was administered on the first, eighth, and 15 days of life, and tumorigenic activity was determined when the mice were 37 to 41 weeks old. Control animals developed an average of 0.13 lung tumor/mouse, whereas animals treated with (+)-diol-epoxide 2, (-)-chrysene 1,2-dihydrodiol, or racemic chrysene 1,2-dihydrodiol had an average of 7.8, 6.5, and 2.5 lung tumors per mouse per µmol of compound administered, respectively. The parent hydrocarbon and all other derivatives tested were essentially inactive in producing lung tumors. With respect to hepatic tumors in male mice, (-)-chrysene 1,2-dihydrodiol was the most active compound tested, and produced 3-, 4-, 6-, and 10-fold more hepatic tumors per mouse per µmol of compound administered than did (+)-diol-epoxide 2, racemic chrysene 1,2-dihydrodiol, chrysene, and (+)-chrysene 1,2-dihydrodiol, respectively. Other derivatives had no significant hepatotumorigenic activity at the doses tested. The high tumorigenic activity of (-)-chrysene 1,2-dihydrodiol and (+)-diol-epoxide 2 on mouse skin and in newborn mice indicate that these compounds are, respectively, proximate and ultimate carcinogenic metabolites of chrysene. The (+)-diol-epoxide 2 isomer of chrysene has absolute configuration such that it is superimposable on the (+)-diol-epoxide 2 isomer of benzo(a)pyrene [(+)-7ß,8{alpha}-dihydroxy-9{alpha},10{alpha}-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene], the ultimate carcinogenic metabolite of benzo(a)pyrene.

1 To whom requests for reprints should be addressed.

Received 5/19/82. Accepted 8/31/82.




This article has been cited by other articles:


Home page
CarcinogenesisHome page
R. L. Chang, A. W. Wood, S. Kumar, R. E. Lehr, N. Shirai, D. M. Jerina, and A. H. Conney
Tumorigenicity of four optically active bay-region 3,4-diol 1,2-epoxides and other derivatives of the nitrogen heterocycle dibenz[c,h]acridine on mouse skin and in newborn mice
Carcinogenesis, November 1, 2000; 21(11): 1997 - 2003.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1983 by the American Association for Cancer Research.